Michael Deininger, MD, PhD, is chief of Hematology and Hematologic Malignancies for Huntsman Cancer Institute (HCI) at the University of Utah. He is a professor in the Department of Medicine at the University of Utah. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly targeted therapies for hematologic malignancies. The major focus of his lab is the molecular basis of resistance to tyrosine kinase inhibitors such as imatinib, a drug used to treat chronic myeloid leukemia and some other types of cancer. They are currently developing biomarker strategies to predict both response and resistance to tyrosine kinase inhibitor therapy. Before joining HCI, Deininger served as chief of the Hematologic Malignancies Section and as leader of the Hematologic Malignancies Program at the Knight Cancer Institute at Oregon Health & Sciences University. He earned his medical degree at the University of Würzburg, Germany, with internship at the Marienhospital Aachen, Germany. He completed his residency in internal medicine as well as a fellowship in hematology and oncology at the Institute of Medical Oncology and Haematology of Nürnberg General Hospital, Germany. After earning his PhD in leukemia biology from Imperial College, London, Deininger completed an additional clinical fellowship in bone marrow transplantation in the Department of Hematology at the University of Leipzig, Germany.